|
CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE: LE MINIMALISME
|
|
Référence |
Chimiothérapie |
nb
cures |
nb
pts |
nb ML |
RO |
SM |
p |
MRC,
1993 |
1.VP16-MTX-CPA-VCR |
3 |
157 |
90 |
60% |
225j |
NS |
2.VP16-MTX-CPA-VCR |
6 |
152 |
84 |
57% |
263j |
3. Ifo-VP16 |
6 |
146 |
82 |
66% |
269j |
MRC,
1996 |
1.VP16-MTX-CPA-VCR |
3 |
154 |
43 |
40% |
141j |
NS |
2. VP16-VCR |
3 |
156 |
46 |
46% |
137j |
MRC,
1996 |
1. VP16 oral |
4 |
171 |
70 |
44% |
130j |
S |
2. VAC ou VP16-VCR |
4 |
168 |
76 |
51% |
183j |
Souhami,
1997 |
1.VP16 oral |
6 |
75 |
- |
32% |
4,8m |
S |
2. CDDP-VP16~VAC |
3x2 |
80 |
- |
46% |
5,9m |
Ettinger,
2002 |
1. CPA-ADR-VCR |
|
46 |
- |
56% |
42s |
S |
2. Ifosfamide |
|
43 |
- |
44% |
43s |
3. VM26 |
|
46 |
- |
43% |
38s |
Références
(1) Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. Br J Cancer 1993; 68(6):1150-1156.
(2) Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party [published erratum appears in Br J Cancer 1996 Sep;74(6):997]. Br J Cancer 1996; 73(3):406-413.
(3) Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party [see comments]. Lancet 1996; 348(9027):563-566.
(4) Souhami RL, Spiro SG, Rudd RM, Ruiz dEM, James LE, Gower NH et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy [see comments]. J Natl Cancer Inst 1997; 89(8):577-580.
(5) Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 2002; 37(3):311-318.
|